INNOVATIVE SOLUTIONS
A growing pipeline of innovative drug candidates for immune mediated diseases. AltruBio has built a differentiated pipeline of biologic therapies targeting diseases of inflammation with products at various stages of development.
A growing pipeline of innovative drug candidates for immune mediated diseases. AltruBio has built a differentiated pipeline of biologic therapies targeting diseases of inflammation with products at various stages of development.
ALTB-168 Neihulizumab
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase II
Phase 2a Psoriatic Arthritis trial completed with proof of clinical efficacy achieved.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase II
Phase 2a anti-TNF α and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with proof of clinical efficacy achieved; continued UC development planned with ALTB-268.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase I
Phase 1b multi-dose steroid refractory acute graft versus host disease trial ongoing
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase I
Investigator sponsored Phase 1 front line acute graft versus host disease trial ongoing.
ALTB-268
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Preclinical
Potency improved version of ALTB-168 for Chronic Inflammatory Disease
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Preclinical
Renal Transplantation Non-Human Primate preclinical studies ongoing.
Mar, 2020
AltruBio
top